المساهمون: Ahmed Osama Gaber, MD, Chair, Department of Surgery

المصدر: Genya [package sert]. East Hanover, NJ: Novart Pharmaceutals Corporatn; 2019.
Chen W, Chen W, LXC, Ghobrl RM, Kloc M. Cohn of mTORC1/mTORC2 and RhoA/ROCK pathways prevents chron rejectn of rat cardc allografts. Transplant Reports. 2018;3(4):21-28.
Hart A, Smh JM, Skeans MA, Gustafson SK, Stewart DE, Cherh WS, Warht JL, Kucheryavaya A, Woodbury M, Snyder JJ, Kaske BL, ranAK. OPTN/SRTR 2015 Annual Data Report: Kney. Am J Transplant. 2017 Jan;17 Suppl 1(Suppl 1):21-116. do 10.1111/ajt.14124.
Hart A, Smh JM, Skeans MA, Gustafson SK, Wk AR, Castro S, Robson A, Warht JL, Snyder JJ, Kaske BL, ranAK. OPTN/SRTR 2017 Annual Data Report: Kney. Am J Transplant. 2019 Feb;19 Suppl 2:19-123. do 10.1111/ajt.15274.
Matas AJ, Smh JM, Skeans MA, Thompson B, Gustafson SK, Stewart DE, Cherh WS, Warht JL, Boyle G, Snyder JJ, ranAK, Kaske BL. OPTN/SRTR 2013 Annual Data Report: kney. Am J Transplant. 2015 Jan;15 Suppl 2:1-34. do 10.1111/ajt.13195.
OPTN/SRTR Annual Data Report - 2011. 2011; https://srtr.transplant.hrsa.gov/annual_reports/2011/Default.aspxTest. Accessed July 29, 2020.
Vanhove T, Goldschmedg R, Kuypers D. Kney Fros: Ors and terventns. Transplantatn. 2017 Apr;101(4):713-726. do 10.1097/TP.0000000000001608.
Nankell BJ, Chapman JR. Chron allograft nephropathy: current concepts and future dectns. Transplantatn. 2006 Mar 15;81(5):643-54. do 10.1097/01.tp.0000190423.82154.01.
Meng XM, Nol-Paterson DJ, Lan HY. flammatory processes renal fros. Nat Rev Nephrol. 2014 Sep;10(9):493-503. do 10.1038/nrneph.2014.114. Epub 2014 Jul 1.
S B, Eecke G, Chang J, Halgo LG, Mengel M, Kaplan B, Halloran PF. Cluster analys of lesns nonselected kney transplant bpss: mrocculatn changes, tubuloterstl flammatn and scarrg. Am J Transplant. 2010 Feb;10(2):421-30. do 10.1111/j.1600-6143.2009.02938.x. Epub 2010 Jan 6.
Naesens M, Kuypers DR, De Vusser K, Vanrenterghem Y, Evenepoel P, Claes K, Bammens B, Meers B, Lerut E. Chron htologal damage early datn bpss an dependent rk factor for late renal allograft faure. Am J Transplant. 2013 Jan;13(1):86-99. do 10.1111/j.1600-6143.2012.04304.x. Epub 2012 Nov 8.
Nankell BJ, Fenton-Lee CA, Kuypers DR, Cheung E, Allen RD, O'Connell PJ, Chapman JR. Effect of htologal damage on long-term kney transplant outcome. Transplantatn. 2001 Feb 27;71(4):515-23. do 10.1097/00007890-200102270-00006.
Cos FG, Grande JP, Larson TS, Gloor JM, Velosa JA, Textor SC, Grf MD, Stegall MD. Kney allograft fros and atrophy early after lg donor transplantatn. Am J Transplant. 2005 May;5(5):1130-6. do 10.1111/j.1600-6143.2005.00811.x.
Nankell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural htory of chron allograft nephropathy. N Engl J Med. 2003 Dec 11;349(24):2326-33. do 10.1056/NEJMoa020009.
Fretto P, Steffes MW, Sutherland DE, Mauer M. Sequentl renal bpss sul-dependent dbet patnts: structural factors assocted wh clal progressn. Kney t. 1995 Dec;48(6):1929-35. do 10.1038/k1995.493.
rah HN, Jackson S, Connae J, Matas A, Ney A, Najafn B, West A, Lentsch N, Erksen J, Bodner J, Kaske B, Mauer M. Angtens blockade kney transplant recnts. J Am Soc Nephrol. 2013 Feb;24(2):320-7. do 10.1681/ASN.2012080777. Epub 2013 Jan 10.
Budde K, Schmouder RL, Brunkhorst R, Nashan B, Lucker PW, Mayer T, Choudhury S, Skerjanec A, Kraus G, Neumayer HH. Fst human trl of FTY720, a novel munomodulator, stable renal transplant patnts. J Am Soc Nephrol. 2002 Apr;13(4):1073-1083. do 10.1681/ASN.V1341073.
Kovar JM, Schmouder R, Barla D, Wang Y, Kraus G. Sgle-dose FTY720 pharmacokets, food effect, and pharmacologal responses healthy subjects. Br J Cl Pharmacol. 2004 May;57(5):586-91. do 10.1111/j.1365-2125.2003.02065.x.
Kovar JM, Schmouder R, Barla D, Rre GJ, Wang Y, Hunt T. Multle-dose FTY720: toleraby, pharmacokets, and lymphocyte responses healthy subjects. J Cl Pharmacol. 2004 May;44(5):532-7. do 10.1177/0091270004264165.
Bohler T, Waer J, Schuetz M, Neumayer HH, Budde K. FTY720 exerts dferentl effects on CD4+ and CD8+ T-lymphocyte subpopulatns expressg chemoke and adhesn receptors. Nephrol Dl Transplant. 2004 Mar;19(3):702-13. do 10.1093/ndt/gfg599.
Kahan BD, Karl JL, Ferguson RM, Lehtman AB, Mulgaonkar S, Gonwa TA, Skerjanec A, Schmouder RL, Chodoff L. Pharmacodynams, pharmacokets, and safety of multle doses of FTY720 stable renal transplant patnts: a multenter, randomed, placebo-controlled, phase study. Transplantatn. 2003 Oct 15;76(7):1079-84. do 10.1097/01.TP.0000084822.01372.AC.
Park S Fele CR, Machado PG, Garc R, Skerjanec A, Schmouder R, Tedesco-Sva H Jr, Meda-Pestana JO. Pharmacoket/pharmacodynam relatnshs of FTY720 kney transplant recnts. Braz J Med Bl Res. 2005 May;38(5):683-94. do 10.1590/S0100-879X2005000500005. Epub 2005 May 25.
Skerjanec A, Tedesco H, Neumayer HH, Cole E, Budde K, Hsu CH, Schmouder R. FTY720, a novel munomodulator de novo kney transplant patnts: pharmacokets and exposure-response relatnsh. J Cl Pharmacol. 2005 Nov;45(11):1268-78. do 10.1177/0091270005279799.
Mulgaonkar S, Tedesco H, Oppenheer F, Walker R, Kunzendorf U, Russ G, Knoflach A, Patel Y, Ferguson R; FTYA121 study group. FTY720/cyclospore regens de novo renal transplantatn: a 1-year dose-fdg study. Am J Transplant. 2006 Aug;6(8):1848-57. do 10.1111/j.1600-6143.2006.01404.x. Epub 2006 Jun 12. Erratum : Am J Transplant. 2006 Dec;6(12):3044.
SalvadorM, Budde K, Charpentr B, Klempnauer J, Nashan B, Pallardo LM, Er J, Schena FP, Eenberger U, Rostag L, HmsA, Aradhye S; FTY720 0124 Study Group. FTY720 versus MMF wh cyclospore de novo renal transplantatn: a 1-year, randomed controlled trl Europe and Australas. Am J Transplant. 2006 Dec;6(12):2912-21. do 10.1111/j.1600-6143.2006.01552.x.
Tedesco-Sva H, Szakaly P, Shoker A, Sommerer C, Yoshura N, Schena FP, Cremer M, HmsA, Mayer H, Lang P; FTY720 2218 Clal Study Group. FTY720 versus mycophenolate mofet de novo renal transplantatn: s-month results of a double-bld study. Transplantatn. 2007 Oct 15;84(7):885-92. do 10.1097/01.tp.0000281385.26500.3b.
Tedesco-Sva H, Lorber M Foster CE, Sollger HW, Mendez R, Carvalho DB, Shapo R, Rajagopalan PR, Mayer H, Slade J, Kahan BD; FTY720A2202 clal study group. FTY720 and everolus de novo renal transplant patnts at rk for delayed graft functn: results of an exploratory one-yr multenter study. Cl Transplant. 2009 Sep-Oct;23(5):589-99. do 10.1111/j.1399-0012.2009.01070.x. Epub 2009 Aug 27.
Hosma AJ, Woodle ES, Abramowz D, Proot P, Vanrenterghem Y; FTY720 Phase Transplant Study Group. FTY720 combed wh tacrolus de novo renal transplantatn: 1-year, multenter, open-label randomed study. Nephrol Dl Transplant. 2011 Nov;26(11):3802-5. do 10.1093/ndt/gfr503. Epub 2011 Sep 12.
Kappos L, Antel J, ComG, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW; FTY720 D2201 Study Group. Oral fgolod (FTY720) for relapsg multle scleros. N Engl J Med. 2006 Sep 14;355(11):1124-40. do 10.1056/NEJMoa052643.
Chen W, Chen S, Chen W, LXC, Ghobrl RM, Kloc M. Screeng RhoA/ROCK hors for the aby to prevent chron rejectn of mouse cardc allografts. Transpl munol. 2018 Oct;50:15-25. do 10.1016/j.tr.2018.06.002. Epub 2018 Jun 6.
Chen W, Ghobrl RM, LXC, Kloc M. hn of RhoA and mTORC2/Rtor by Fgolod (FTY720) duces p21-actated kase 1, PAK-1 and ampls podosomes mouse peroneal macrophages. munoblogy. 2018 Nov;223(11):634-647. do 10.1016/j.b.2018.07.009. Epub 2018 Jul 7.
CONSORT Group. CONSORT Transparent reportg of trls. 2010; http://www.consort-statement.org/consort-2010Test. Accessed July 29, 2020.
Budde K, L Schmouder R, Nashan B, Brunkhorst R, W Lucker P, Mayer T, Brookman L, Nedelman J, Skerjanec A, Bohler T, Neumayer HH. Pharmacodynams of sgle doses of the novel munosuppressant FTY720 stable renal transplant patnts. Am J Transplant. 2003 Jul;3(7):846-54. do 10.1034/j.1600-6143.2003.00130.x.
A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Fingolimod for the Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT05285878Test

المؤلفون: Veloxis Pharmaceuticals

المساهمون: Ahmed Osama Gaber, MD, Director, Houston Methodist J.C. Walter Jr. Transplant Center

المصدر: Kney Dease: provg Global Outcomes (KDO) Transplant Work Group. KDO clal practe guele for the care of kney transplant recnts. Am J Transplant. 2009 Nov;9 Suppl 3:S1-155. do 10.1111/j.1600-6143.2009.02834.x.
Young CJ, Gaston RS. Renal transplantatn black Amerans. N Engl J Med. 2000 Nov 23;343(21):1545-52. do 10.1056/NEJM200011233432107. No abstract avaable.
Narayanan M, Pankewycz O, Shab F, Wand A, McCague K, Chan L. Long-term outcomes Afran Ameran kney transplant recnts under contemporary munosuppressn: a four-yr analys of the Mycophenol ac Observatnal REnal transplant (MORE) study. Cl Transplant. 2014 Feb;28(2):184-91. do 10.1111/ctr.12294. Epub 2013 Dec 24.
Lamb KE, LodhS, Mer-Krsche HU. Long-term renal allograft surval the Uned States: a cral reappraal. Am J Transplant. 2011 Mar;11(3):450-62. do 10.1111/j.1600-6143.2010.03283.x. Epub 2010 Oct 25.
Patel SJ, SukWN, Loucks-DeVos J, Gravs EA, Nguyen DT, Knht RJ, Kuten SA, Moore LW, Teeter LD, Gaber LW, Gaber AO. Dparate rates of acute rejectn and donor-spec antods among hh-munolog rk renal transplant subgroups receg anthymocyte globul ductn. Transpl t. 2016 Aug;29(8):897-908. do 10.1111/tr12791. Epub 2016 Jul 7.
Bunnapradt S, CchanowskK, West-Thlke P, Mulgaonkar S, Rostag L, Vasudev B, Budde K; MELT vestators. Conversn from twe-day tacrolus to once-day extended release tacrolus (LCPT): the phase randomed MELT trl. Am J Transplant. 2013 Mar;13(3):760-9. do 10.1111/ajt.12035. Epub 2012 Dec 21.
Budde K, Bunnapradt S, Gryo JM, CchanowskK, Denny JE, Sva HT, Rostag L; Envarsus study group. Novel once-day extended-release tacrolus (LCPT) versus twe-day tacrolus de novo kney transplants: one-year results of Phase double-bld, randomed trl. Am J Transplant. 2014 Dec;14(12):2796-806. do 10.1111/ajt.12955. Epub 2014 Oct 2.
Gaber AO, Alloway RR, Bodzk K, Kaplan B, Bunnapradt S. Conversn from twe-day tacrolus capsules to once-day extended-release tacrolus (LCPT): a phase 2 trl of stable renal transplant recnts. Transplantatn. 2013 Jul 27;96(2):191-7. do 10.1097/TP.0b013e3182962cc1.
Bunnapradt S, Rostag L, Alloway RR, West-Thlke P, Denny J, Mulgaonkar S, Budde K. LCPT once-day extended-release tacrolus tablets versus twe-day capsules: a pooled analys of two phase 3 trls portant de novo and stable kney transplant recnt subgroups. Transpl t. 2016 May;29(5):603-11. do 10.1111/tr12770. Epub 2016 Apr 3.
Trofe-Clark J, Brennan DC, West-Thlke P, Mone MC, L MA, Neubauer R, Nro V, Bloom RD. Results of ASERTAA, a Randomed Prospecte Crossover Pharmacogenet Study of medte-Release Versus Extended-Release Tacrolus Afran Ameran Kney Transplant Recnts. Am J Kney D. 2018 Mar;71(3):315-326. do 10.1053/j.ajkd.2017.07.018. Epub 2017 Nov 20.
Langone A, Steberg SM, Gedaly R, Chan LK, Shah T, SethKD, Nro V, Morgan JC; STRATO vestators. Swchg STudy of Kney TRansplant PAtnts wh Tremor to LCP-TacrO (STRATO): an open-label, multenter, prospecte phase 3b study. Cl Transplant. 2015 Sep;29(9):796-805. do 10.1111/ctr.12581. Epub 2015 Aug 6.
Kuypers DR, Claes K, Evenepoel P, Maes B, Vanrenterghem Y. Clal effacy and toxy profe of tacrolus and mycophenol ac relatn to combed long-term pharmacokets de novo renal allograft recnts. Cl Pharmacol Ther. 2004 May;75(5):434-47. do 10.1016/j.clpt.2003.12.009.
Wsett RP, Arheart K, Stratta RJ, Alloway R, Wks MN, Gaber AO, Hathaway DK. Evaluatn of an munosuppressant se effect strument. Prog Transplant. 2004 Sep;14(3):210-6, 240. do 10.1177/152692480401400306.
Staatz CE, Tett SE. Clal pharmacokets and pharmacodynams of tacrolus sol organ transplantatn. Cl Pharmacoket. 2004;43(10):623-53. do 10.2165/00003088-200443100-00001.
Kuypers DR, Peeters PC, Sennesael JJ, Knda MN, Vrens B, Krtanto P, Dobbels F, Vanrenterghem Y, Kanaan N; ADMAD Study Team. proved adherence to tacrolus once-day formulatn renal recnts: a randomed controlled trl usg electron monorg. Transplantatn. 2013 Jan 27;95(2):333-40. do 10.1097/TP.0b013e3182725532.
Ho ET, Wong G, Cra JC, Chapman JR. Once-day extended-release versus twe-day standard-release tacrolus kney transplant recnts: a systemat revw. Transplantatn. 2013 May 15;95(9):1120-8. do 10.1097/TP.0b013e318284c15b.
Beckebaum S, cob S, Swe D, Sotopoulos GC, Saner F, Kaer G, Radtke A, Kle CG, Er Y, de Geest S, Paul A, Gerken G, CnatVR. Effacy, safety, and munosuppressant adherence stable ler transplant patnts converted from a twe-day tacrolus-based regen to once-day tacrolus extended-release formulatn. Transpl t. 2011 Jul;24(7):666-75. do 10.1111/j.1432-2277.2011.01254.x. Epub 2011 Apr 5.
Doesch AO, Mueller S, Konstand M, Cel S, Erbel C, Krten A, Frankenste L, Koch A, Dengler TJ, Ehlermann P, Zugck C, De Geest S, Katus HA. creased adherence after swch from twe day calceur hor based treatment to once day modd released tacrolus heart transplantatn: a pre-experental study. Transplant Proc. 2010 Dec;42(10):4238-42. do 10.1016/j.transproceed.2010.09.074.
Maldonado G, Greenland S. Sulatn study of confounder-selectn strategs. Am J Epeml. 1993 Dec 1;138(11):923-36. do 10.1093/oxfordjournals.aje.a116813.
Wasserman L. Bayesn Model Selectn and Model Averagg. J Math Psychol. 2000 Mar;44(1):92-107. do 10.1006/jmps.1999.1278.
Evaluation of Early Dose Escalation Using Extended-Release Tacrolimus (Envarsus XR®) to Reduce Acute Rejection and Donor Specific Antibodies in African American Renal Transplant Recipients

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT04665310Test

المؤلفون: Center for Cell and Gene Therapy, Baylor College of Medicine

المساهمون: Ahmed Osama Gaber, MD, Principal Investigator

المصدر: A Double-blind, Randomized, Controlled Dose Escalation Trial of Autologuous Mesenchymal Stromal Cells in Living Donor Kidney Transplant Recipients

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT03478215Test

المساهمون: Ahmed Osama Gaber, MD, Director, Houston Methodist Transplant Center

المصدر: Brennan DC, Agha Bohl DL, Schnzler MA, Hardger KL, Lockwood M, Torrence S, Schuessler R, Roby T, Gaudreault-Keener M, Storch GA. cence of BK wh tacrolus versus cyclospore and pact of preempte munosuppressn reductn. Am J Transplant. 2005 Mar;5(3):582-94. do 10.1111/j.1600-6143.2005.00742.x. Erratum : Am J Transplant. 2005 Apr;5(4 Pt 1):839.
AlSH, Chandraker A, DeCapr JA. hn of Sn vus 40 large T anten helase acty by fluoroquolones. Ant Ther. 2007;12(1):1-6.
Leung AY, Chan MT, Yuen KY, Cheng VC, Chan KH, Wong CL, Lng R, L AK, Kwong YL. Crofloxac decreased polyoma BK vus load patnts who underwent allogene hematopot stem cell transplantatn. Cl fect D. 2005 Feb 15;40(4):528-37. do 10.1086/427291. Epub 2005 Jan 21.
Mler AN, Glode A, Hogan KR, Schaub C, Kramer C, Stuart RK, Costa LJ. Effacy and safety of crofloxac for prophylax of polyomavus BK vus-assocted hemorrhag cyst allogene hematopot stem cell transplantatn recnts. Bl Blood Marrow Transplant. 2011 Aug;17(8):1176-81. do 10.1016/j.bbmt.2010.12.700. Epub 2010 Dec 23.
GabardS, Waar SS, Mart S, Roberts K, Chen J, BorgL, Sheashaa H, Dyer C, Malek SK, Tulls SG, Vadel N, Grafals M, AbdR, Najafn N, Mford E, Chandraker A. Evaluatn of fluoroquolones for the preventn of BK vem after renal transplantatn. Cl J Am Soc Nephrol. 2010 Jul;5(7):1298-304. do 10.2215/CJN.08261109. Epub 2010 May 27.
Ciprofloxacin for Prevention of BK Infection in Renal Transplant Recipients

الوصول الحر: https://clinicaltrials.gov/ct2/show/NCT01789203Test